The Children's Oncology Drug Alliance (CODA) was formed to develop the first range of drugs specifically for the treatment of childhood cancers.

Of all the drugs used in children to treat cancer, only one has been developed specifically for children, and that is for the treatment of acute lymphoblastic leukaemia.

All other drugs used in children have been developed for the treatment of adult cancers, then approval for their use in children sought as an after-thought.

This approach has failed to take account of the fact that childhood cancers are different to adult cancers, and that the lifelong consequences of cancer drug side-effects can be far more devastating in a child than in an adult.

CODA has one purpose – to develop the first range of drugs specifically for the treatment of childhood cancers, with the lifetime consequences of those treatments a key consideration.

CODA unites the research and resources of five leading organisations in Australia and the US.

The Australian members are:

  • Childhood cancer research charity, The Kids' Cancer Project
  • The University of New South Wales and its commercial arm, NewSouth Innovations
  • Biotechnology company, Novogen Limited

The US member is:

  • Nationwide Children's Hospital in Columbus, Ohio